Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Travere Therapeutics, Inc. (TVTX)

Travere Therapeutics Q3 sales rise to $220.2 million; net loss of $52.3 million

Mixed Impact 3 of 5 earnings Written later

Travere Therapeutics reported third quarter 2026 U.S. net product sales of $220.2 million, up from $113.2 million a year earlier, with FILSPARI accounting for $200.2 million. The company swung to a GAAP net loss of $52.3 million, or $0.55 per basic share, from net income of $25.7 million a year earlier, mainly because of a $113.1 million IPR&D expense tied to its Everest Medicines licensing agreement for civorebrutinib.

Key points

  • U.S. net product sales were $220.2 million in Q3 2026 versus $113.2 million in Q3 2025; FILSPARI sales were $200.2 million, up 120% year over year.
  • GAAP net loss was $52.3 million, or $0.55 per basic share, compared with net income of $25.7 million, or $0.29 per share, in Q3 2025.
  • Non-GAAP adjusted net loss was $29.6 million, or $0.31 per basic share, for Q3 2026.
  • Cash, cash equivalents and marketable securities were $471.8 million as of September 30, 2026. CEO Eric Dube will hand over to Bradley Campbell effective December 1, 2026.

The filing

CompanyTravere Therapeutics, Inc. (TVTX)
Form8-K, current report
Filed with the SECNov 2, 2026, 4:05 PM ET
Accession number0001438533-26-000074

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 02, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.